GEICAM – Spanish Breast Cancer Group

Institution (Nonprofit)

Homepage ROR

Also Known As

GEICAM – Spanish Breast Cancer Group, Grupo Español de Investigación en Cáncer de Mama · Acronym: GEICAM

700

Publications

64K

Citations

Authors

132

Concepts

About

GEICAM – Spanish Breast Cancer Group is a nonprofit institution in Alcobendas, Spain known for breast cancer, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	299	19.5K
2	Health Sciences	19	169	11.8K
3	Engineering	6	16	888
4	Natural Sciences	4	8	170
5	Language Studies	1	1	20

GEICAM – Spanish Breast Cancer Group

700

Publications

64K

Citations

Page 1

	Year	Citations
Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation Jennifer K. Litton, Hope S. Rugo, Johannes Ettl, New England Journal of Medicine	2018	2K
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) Journal of Clinical Oncology	2020	917
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer Dennis J. Slamon, Patrick Neven, Stephen Chia, New England Journal of Medicine	2019	797
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial Sibylle Loibl, Joyce O’Shaughnessy, Michael Untch, The Lancet Oncology Breast OncologyParp Inhibitor VeliparibMedicinePharmacologyBreast Cancer	2018	744
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Sibylle Loibl, Fabrice André, Thomas Bachelot, Annals of Oncology Surgical OncologyBreast OncologyEarly Breast CancerMedicineCancer Management	2023	684
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer Francesco Schettini, Núria Chic, Fara Brasó‐Maristany, npj Breast Cancer	2021	655
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial Miguel Martín, Frankie A. Holmes, Bent Ejlertsen, The Lancet Oncology 5-Year AnalysisBreast OncologyOncologyHealth SciencesClinical Trials	2017	578
Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. DJ Slamon, W. Eiermann, Nicholas J. Robert, Cancer Research Breast OncologyOncologyCyclophosphamide FollowedBreast Cancer PatientsCancer Management	2009	554
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes Dominik Dahl, Yukiko Onishi, Paul Norwood, JAMA	2022	512
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial Stephen Johnston, Masakazu Toi, Joyce O’Shaughnessy, The Lancet Oncology Endocrine OncologyBreast OncologyMedicinePreplanned Interim AnalysisPharmacology	2022	507

Page 1